<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036621</url>
  </required_header>
  <id_info>
    <org_study_id>CA161-006</org_study_id>
    <nct_id>NCT00036621</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      This clinical trial will assess whether BMS-275291 can be administered safely in combination&#xD;
      with standard adjuvant therapy for early breast cancer and whether plasma concentrations at&#xD;
      trough exceed a target minimum.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-275291</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed pathologic stage 1c-IIIA adenocarcinoma of the breast which&#xD;
             has been completely resected.&#xD;
&#xD;
          2. Systemic therapy is planned according to one of the following three regimens:&#xD;
&#xD;
               -  Tamoxifen (20mg) given orally once per day&#xD;
&#xD;
               -  Adriamycin (60 mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1),&#xD;
                  repeated every 21 days for four courses (to begin within 8 weeks after definitive&#xD;
                  surgery)&#xD;
&#xD;
               -  Adriamycin (60mg/m2 IV on Day 1) plus cyclophosphamide (600mg/m2 IV on Day 1),&#xD;
                  repeated every 21 days for four courses, followed by Taxol (175mg/m2 IV on Day&#xD;
                  85) repeated every 21 days for four courses (to begin within 8 weeks after&#xD;
                  definitive surgery).&#xD;
&#xD;
          3. ECOG performance status 0 or 1.&#xD;
&#xD;
          4. Adequate organ function as evidenced by:&#xD;
&#xD;
               -  ANC &gt; 1500/mm3&#xD;
&#xD;
               -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
               -  Serum Creatine &lt; 1.5 ULN&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
               -  AST &lt; 2 x ULN&#xD;
&#xD;
          5. Patients to receive adriamycin must have LVEF &gt; 50% or acceptable function per the&#xD;
             institutional practice as assessed by MUGA.&#xD;
&#xD;
          6. Signed informed consent.&#xD;
&#xD;
          7. Women age =/&gt; 18 years&#xD;
&#xD;
          8. Patients must have recovered from reversible adverse events of prior surgery and any&#xD;
             radiation therapy.&#xD;
&#xD;
          9. Women of childbearing potential must have a serum or urine pregnancy test within 72&#xD;
             hours prior to the start of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients in whom breast cancer is present at the margin or surgical resection are not&#xD;
             eligible in this study. Patients suspicious for residual disease following resection&#xD;
             are not eligible.&#xD;
&#xD;
          2. Prior chemotherapy or immunotherapy for breast cancer.&#xD;
&#xD;
          3. Documented metastatic breast cancer.&#xD;
&#xD;
          4. Other malignancy (except carcinoma in situ of the cervix or surgically treated&#xD;
             non-melanoma skin cancer) within 5 years of study entry.&#xD;
&#xD;
          5. Pregnant or breastfeeding females.&#xD;
&#xD;
          6. Women of child bearing potential not employing adequate contraception.&#xD;
&#xD;
          7. History of autoimmune diseases such as systemic lupus, rheumatoid arthritis,&#xD;
             scleroderma.&#xD;
&#xD;
          8. Any serious underlying medical conditions which would impair the ability ot the&#xD;
             patient to receive the planned treatment or which may interfere with the completion of&#xD;
             this trial.&#xD;
&#xD;
          9. Planned chemotherapy, hormonal therapy or biological therapy other than those&#xD;
             described above. Patients should not be enrolled in any other clinical trials. Use of&#xD;
             other investigational agents is not permitted.&#xD;
&#xD;
         10. Any condition that does not permit compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>May 11, 2002</study_first_submitted>
  <study_first_submitted_qc>May 11, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2002</study_first_posted>
  <disposition_first_submitted>February 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 2, 2010</disposition_first_posted>
  <last_update_submitted>February 27, 2010</last_update_submitted>
  <last_update_submitted_qc>February 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

